Atara Biotherapeutics, Inc. (ATRA) financial statements and ratios from SEC XBRL: revenue $120.77M (TTM), net margin 27.1%, revenue growth -6.3% YoY. Income statement, balance sheet, cash flow, and valuation. First-party data.
| Revenue (TTM) | $120.77M |
| Net Margin | 27.1% |
| Revenue Growth (YoY) | -6.3% |
| EPS Growth (YoY) | -122.9% |
| FCF Growth (YoY) | -26.1% |
| Price / Sales | 19.17 |
| FCF Yield | -46.1% |
| Altman Z-Score | -127.41 (distress) |
| Sector P/E (Healthcare) | 21.7 |
ATRA overview · ATRA earnings · ATRA KPIs · ATRA investor relations · ATRA ownership · ATRA peers · ATRA filings
Data sourced from U.S. SEC EDGAR XBRL filings. Not personalized investment advice.